Drugs in Dev.
Cardiology/Vascular Diseases
Undisclosed
Belgium 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dapagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion
Details : Dapagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 11, 2021
Lead Product(s) : Dapagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cardiomyocytes
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : BlueRock Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Cardiomyocytes
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : BlueRock Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
